Neuronetics Inc (STIM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuronetics Inc (STIM) has a cash flow conversion efficiency ratio of -0.552x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.42 Million) by net assets ($17.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Neuronetics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Neuronetics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Neuronetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neuronetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuronetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BaoMinh Insurance Corp
VN:BMI
|
0.005x |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
0.025x |
|
J W Mays Inc
NASDAQ:MAYS
|
0.028x |
|
Autocount Dotcom Berhad
KLSE:0276
|
0.035x |
|
Nexstim Oyj
HE:NXTMH
|
0.099x |
|
Heng Sheng Holding Group Limited
KQ:900270
|
0.011x |
|
JITF Infralogistics Limited
NSE:JITFINFRA
|
0.323x |
|
Aditya Birla Money Limited
NSE:BIRLAMONEY
|
0.060x |
Annual Cash Flow Conversion Efficiency for Neuronetics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Neuronetics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Neuronetics Inc (STIM) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.24 Million | $-20.37 Million | -0.776x | +20.35% |
| 2024-12-31 | $31.80 Million | $-31.00 Million | -0.975x | -4.03% |
| 2023-12-31 | $34.19 Million | $-32.04 Million | -0.937x | -73.94% |
| 2022-12-31 | $57.06 Million | $-30.74 Million | -0.539x | -63.97% |
| 2021-12-31 | $85.17 Million | $-27.98 Million | -0.329x | +70.50% |
| 2020-12-31 | $25.49 Million | $-28.39 Million | -1.114x | -74.82% |
| 2019-12-31 | $47.85 Million | $-30.48 Million | -0.637x | -119.78% |
| 2018-12-31 | $71.04 Million | $-20.59 Million | -0.290x | -601.07% |
| 2017-12-31 | $-192.65 Million | $-11.14 Million | 0.058x | +19.96% |
| 2016-12-31 | $-177.12 Million | $-8.54 Million | 0.048x | -- |
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a p… Read more